Fig. 5.
Effects of twice daily treatments with 5 μmol/L of SpA4-anti-bcr (•) or SpA4-anti-b3a2 (□) on the growth and survival of CML cells derived from (A) patient 1, (B) patient 2, and (C) patient 3, and (D) of bone marrow from a healthy individual. No treatment: (⊞). Cell numbers are the average obtained from duplicate wells.
